SCHEMBL6026486

SCHEMBL6026486

CCC(Br)c1nc2cc(C#N)ccc2c(=O)n1-c1ccc(C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.56
CXCR3 P49682 4/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
PDE10A Q9Y233 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
CASP1 P29466 1/20 0.37
RECQL P46063 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KCNH2 Q12809 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
TDP2 O95551 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6026829 0.76 TRPV1 (0.44) TRPV1CXCR3KMT2AMEN1HTT
Alcohol SCHEMBL26655335 0.73 TRPV1 (0.91) TRPV1CXCR3KMT2APDE10AKCNH2
SCHEMBL15957766 0.72 TRPV1 (0.58) TRPV1CXCR3HTTPDE10AALDH1A1
SCHEMBL29383546 0.72 TRPV1 (1.00) TRPV1CXCR3KMT2APDE10AKCNH2
SCHEMBL1066896 0.72 TRPV1 (1.00) TRPV1CXCR3KMT2APDE10AKCNH2
SCHEMBL1663702 0.71 TRPV1 (0.77) TRPV1CXCR3KMT2APDE10AALDH1A1
SCHEMBL12374601 0.69 TRPV1 (0.51) TRPV1ALDH1A1KDM4EGAAGLA
SCHEMBL1664439 0.69 TRPV1 (0.74) TRPV1CXCR3HTTPDE10AALDH1A1
SCHEMBL10446275 0.68 TRPV1 (0.56) TRPV1CXCR3KMT2AMEN1ALDH1A1
SCHEMBL1663818 0.67 TRPV1 (0.64) TRPV1CXCR3KMT2AMEN1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264420-A1 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2006-11-23 US disclosed
EP-1539180-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2006-08-30 EP disclosed
EP-1539180-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-06-15 EP disclosed
US-20040048853-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2004-03-11 US disclosed
WO-2004018058-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264420-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 TRPV1 4539/4885CXCR3 3073/4885KMT2A 1458/4885
US-20040048853-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 TRPV1 4539/4885CXCR3 3073/4885KMT2A 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.